Immunosupressant macrolides

AntiRat Macrophages,Adsorbed IgG Fract(Poly,rabbit IgG)10mg

InformationBelnacasan (VX-765) is a potent and selective inhibitor ofcaspase-1withKiof 0.8 nM in a cell-free assay. Phase 2.In vitroVX-765 is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and

General description The immune system can recognize and destroy tumors. Cytotoxic T lymphocytes (CTLs) kill neoplastic (or virally infected) cells after recognizing antigenic peptides bound to major histocompatibility complex (MHC) class I

InformationBMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.TargetsPD-1/PD-L1 (Cell-free

InformationBMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.TargetsPD-1/PD-L1 (Cell-free

InformationBMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.TargetsPD-1/PD-L1 (Cell-free

InformationBMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.TargetsPD-1/PD-L1 (Cell-free

InformationBMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.TargetsPD-1/PD-L1 (Cell-free

InformationBMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.TargetsPD-1/PD-L1 (Cell-free

InformationBMS-1166 BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.TargetsPD-1/PD-L1 interaction 1.4 nMIn vitroBMS-1166 presents low toxicity towards tested cell lines and blocks the

InformationBMS-582949 BMS-582949 (PS540446) is a potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13nM,inhibiting both p38 kinase activity and activation of p38.In vitroBMS-582949 is found to inhibit p38

Botensilimab (anti-CTLA4), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab (anti-CTLA4) can be used for the research of cancer.